Arcutis' ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

(marketscreener.com) ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially insured patients, effective November 18, 2022ZORYVE is a once-daily non-steroidal cream and the first and only topical PDE4 inhibitor approved for use in plaque psoriasis, including all affected areas of the body, on July 29Arcutis announced the commercial...https://www.marketscreener.com/quote/stock/ARCUTIS-BIOTHERAPEUTICS-101779542/news/Arcutis-ZORYVE-Roflumilast-Cream-0-3-Added-to-Express-Scripts-Inc-National-Formularies-in-th-42344381/?utm_medium=RSS&utm_content=20221117